Morgan Stanley’s Moleculin Biotech MBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $55.9K | Buy |
20,036
+20,000
| +55,556% | +$51.1K | ﹤0.01% | 6467 |
|
|
2026
Q1 | $83 | Hold |
36
| – | – | ﹤0.01% | 7835 |
|
|
2025
Q4 | $119 | Sell |
36
-1
| -3% | -$9 | ﹤0.01% | 7691 |
|
|
2025
Q3 | $491 | Hold |
37
| – | – | ﹤0.01% | 7498 |
|
|
2025
Q2 | $280 | Hold |
37
| – | – | ﹤0.01% | 7526 |
|
|
2025
Q1 | $901 | Buy |
37
+20
| +118% | +$672 | ﹤0.01% | 7294 |
|
|
2024
Q4 | $724 | Sell |
17
-1
| -6% | -$61 | ﹤0.01% | 7309 |
|
|
2024
Q3 | $1.27K | Buy |
18
+1
| +6% | +$72 | ﹤0.01% | 7193 |
|
|
2024
Q2 | $1.5K | Hold |
17
| – | – | ﹤0.01% | 7102 |
|
|
2024
Q1 | $2.5K | Hold |
17
| – | – | ﹤0.01% | 7030 |
|
|
2023
Q4 | $5.44K | Hold |
17
| – | – | ﹤0.01% | 6819 |
|
|
2023
Q3 | $2.71K | Hold |
17
| – | – | ﹤0.01% | 7062 |
|
|
2023
Q2 | $3.67K | Hold |
17
| – | – | ﹤0.01% | 7050 |
|
|
2023
Q1 | $6.08K | Hold |
17
| – | – | ﹤0.01% | 7011 |
|
|
2022
Q4 | $6.72K | Buy |
17
+1
| +6% | +$422 | ﹤0.01% | 7071 |
|
|
2022
Q3 | $6K | Hold |
16
| – | – | ﹤0.01% | 7209 |
|
|
2022
Q2 | $9K | Hold |
16
| – | – | ﹤0.01% | 7246 |
|
|
2022
Q1 | $11K | Hold |
16
| – | – | ﹤0.01% | 7376 |
|
|
2021
Q4 | $11K | Hold |
16
| – | – | ﹤0.01% | 7444 |
|
|
2021
Q3 | $18K | Sell |
16
-10
| -38% | -$11.7K | ﹤0.01% | 7137 |
|
|
2021
Q2 | $36K | Hold |
26
| – | – | ﹤0.01% | 6799 |
|
|
2021
Q1 | $39K | Buy |
+26
| New | +$47.6K | ﹤0.01% | 6464 |
|
|
2020
Q1 | – | Sell |
-16
| Closed | -$32K | – | 6644 |
|
|
2019
Q4 | $32K | Hold |
16
| – | – | ﹤0.01% | 5979 |
|
|
2019
Q3 | $39K | Buy |
16
+2
| +14% | +$5.17K | ﹤0.01% | 5815 |
|
|
2019
Q2 | $39K | Buy |
14
+8
| +133% | +$21.7K | ﹤0.01% | 5708 |
|
|
2019
Q1 | $10K | Hold |
6
| – | – | ﹤0.01% | 6183 |
|
|
2018
Q4 | $13K | Hold |
6
| – | – | ﹤0.01% | 6114 |
|
|
2018
Q3 | $20K | Hold |
6
| – | – | ﹤0.01% | 6135 |
|
|
2018
Q2 | $22K | Buy |
6
+1
| +20% | +$4.09K | ﹤0.01% | 6127 |
|
|
2018
Q1 | $22K | Sell |
5
-1
| -17% | -$4.33K | ﹤0.01% | 6107 |
|
|
2017
Q4 | $23K | Hold |
6
| – | – | ﹤0.01% | 6043 |
|
|
2017
Q3 | $32K | Buy |
6
+1
| +20% | +$5.28K | ﹤0.01% | 5906 |
|
|
2017
Q2 | $21K | Hold |
5
| – | – | ﹤0.01% | 6068 |
|
|
2017
Q1 | $13K | Buy |
+5
| New | +$17.5K | ﹤0.01% | 6182 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6383 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$14.4K | – | 6275 |
|
|
2016
Q2 | $8K | Buy |
+1
| New | +$16.2K | ﹤0.01% | 6107 |
|
Other funds holding MBRX
XT
TRCT
EI
Morgan Stanley's MBRX Position: Q2 2026 in Review
Morgan Stanley increased its Moleculin Biotech (MBRX) stake by 55,556% in Q2 2026, buying an estimated $51.1K and bringing the position to 20,036 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6467.
Morgan Stanley first reported a position in MBRX in Q2 2016 and has held it in 35 quarters since. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.
- Morgan Stanley held 20,036 shares of Moleculin Biotech worth $55.9K as of Q2 2026.
- Morgan Stanley bought 20,000 Moleculin Biotech shares in Q2 2026, an estimated $51.1K.
- Moleculin Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6467 holding.
- Morgan Stanley first reported a position in Moleculin Biotech in Q2 2016 and has held it in 35 quarters since.
- 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.